How can the gene therapy industry drive down the cost of goods to better serve patients?
Jun
13
2023
On demand

How can the gene therapy industry drive down the cost of goods to better serve patients?

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
How can the gene therapy industry drive down the cost of goods to better serve patients?

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

The cost per dose of viral vector therapeutics is a major challenge for the widespread accessibility of gene therapy products, driven by a high cost of goods and manufacturing expenses.

In this webinar, we will identify the components that contribute to these high costs and pinpoint the biggest challenges the industry must overcome to reduce the cost per dose. We will discuss how tools such as process intensification (PI) and cost modeling can help us understand the main cost drivers and the impact process optimization can have on the cost per dose.

  • Discover why viral vector therapies are so expensive
  • Explore how manufacturers and solution providers can work together to ultimately make these drugs more cost-efficient to manufacture and ultimately reduce cost per dose
  • Dive into case study examples showing how the use of PI can help reduce the cost of manufacturing and ultimately cost per dose
Emmanuelle Cameau
Emmanuelle Cameau
Strategic Technology Partnership Leader Cytiva, Genomic Medicines

Emmanuelle Cameau is a Senior Bioreactor Applications Scientist within the Scientific Laboratory Services (SLS) at Pall Biotech. Highly skilled in the field of cell culture applications and with 10+ years of experience, Emmanuelle previously held positions as a Bioprocess Specialist at Pall, and a Biotech Process Sciences Upstream Process Development Engineer at Merck Serono. She received her Biotechnology Engineer diploma from the former Ecole Supérieure d’Ingénieurs de Luminy (now Polytech Marseille).

SPEAKERS

Emmanuelle Cameau
Emmanuelle Cameau
Strategic Technology Partnership Leader Cytiva, Genomic Medicines

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual
27 June
in 63
Days
Register
Precision in production: optimizing monitoring and quality control for high-value plasmids

Precision in production: optimizing monitoring and quality control for high-value plasmids

Oleksandr Karpenko
6 June
in 42
Days
Register
Advancing cell therapy: innovations in polymer-based encapsulation and delivery

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

B Yevgeniy, O Veiseh, M Delic-Schlumbohm et al.
5 June
in 41
Days
Register
Pure and simple: understanding LNP analytics for better mRNA-based drugs

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe
29 May
in 34
Days
Register
Empowering patient care: in-process and quality control solutions for cellular therapies

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz
23 May
in 28
Days
Register